KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) – Equities research analysts at Jefferies Financial Group upped their FY2027 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a note issued to investors on Friday, September 9th. Jefferies Financial Group analyst M. Raycroft now anticipates that the specialty pharmaceutical company will post earnings per share of $5.03 for the year, up from their previous forecast of $4.91. The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($4.28) per share.

Several other brokerages have also recently issued reports on KALV. SVB Leerink cut their target price on KalVista Pharmaceuticals from $51.00 to $45.00 and set an "outperform" rating on the stock in a research report on Friday, July 8th. Needham & Company LLC cut their target price on KalVista Pharmaceuticals from $42.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, July 8th.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) last announced its quarterly earnings data on Thursday, July 7th. The specialty pharmaceutical company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.06) by $0.08.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new stake in shares of KalVista Pharmaceuticals in the second quarter valued at $26,000. Quantbot Technologies LP purchased a new position in shares of KalVista Pharmaceuticals in the second quarter valued at $34,000. Amalgamated Bank purchased a new position in shares of KalVista Pharmaceuticals in the first quarter valued at $54,000. BNP Paribas Arbitrage SA grew its position in shares of KalVista Pharmaceuticals by 236.8% in the second quarter. BNP Paribas Arbitrage SA now owns 5,958 shares of the specialty pharmaceutical company's stock valued at $59,000 after purchasing an additional 4,189 shares in the last quarter. Finally, PDT Partners LLC purchased a new position in shares of KalVista Pharmaceuticals in the second quarter valued at $139,000.

Insider Buying and Selling

In related news, CEO Thomas Andrew Crockett sold 1,797 shares of KalVista Pharmaceuticals stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $14.96, for a total transaction of $26,883.12. Following the sale, the chief executive officer now directly owns 112,178 shares in the company, valued at $1,678,182.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.30% of the stock is currently owned by corporate insiders.

About KalVista Pharmaceuticals

(Get Rating)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also

• Get a free copy of the StockNews.com research report on KalVista Pharmaceuticals (KALV)
• Can Electronic Arts Buck the Downturn in Videogaming?
• Dollar General is the Big Fish in Little Ponds Across the U.S.
• Here's Why the CPI Report will Dictate the Market Bottom
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.